Luke V. Selby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luke V. Selby has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Vivian E. Strong
Memorial Sloan Kettering Cancer Center, New York, NY
10 shared publications Daniel G. Coit
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
5 shared publicationsAubrey C. Swilling
Department of Surgery, Colorectal & Oncologic Surgery Division, The University of Kansas Medical Center, Kansas City, USA
4 shared publicationsCorey A. Hounschell
Department of Surgery, Colorectal & Oncologic Surgery Division, The University of Kansas Medical Center, Kansas City, USA
4 shared publications- Daniel D. Sjoberg
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
3 shared publications - Mazin Al-Kasspooles
Department of Surgery, University of Kansas Medical Center, Kansas City, KS 66211, USA
3 shared publications
Latest Publications
- Open Access
- 9 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 3867
ASO Visual Abstract: Volume-Outcome Relationships in Total Mesorectal Excision Quality and Grading: A National Cancer Database Study
- 9 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 3867
Open AccessASO Visual Abstract: Volume-Outcome Relationships in Total Mesorectal Excision Quality and Grading: A National Cancer Database Study
- 17 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 3806-3813
Volume–Outcome Relationships in Total Mesorectal Excision Quality and Grading: A National Cancer Database Study
Total mesorectal excision (TME) is the surgical standard for mid-to-low rectal cancer, and the Commission on Cancer Standard 5.7 requires documentation of
- 17 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 3806-3813
Volume–Outcome Relationships in Total Mesorectal Excision Quality and Grading: A National Cancer Database Study
Total mesorectal excision (TME) is the surgical standard for mid-to-low rectal cancer, and the Commission on Cancer Standard 5.7 requires documentation of
- 13 February 2026
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 242 (3) , 512-514
Invited Commentary: Should We Be Doing Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma?
- 13 February 2026
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 242 (3) , 512-514
Invited Commentary: Should We Be Doing Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma?
- Open Access
Predictors of Peritoneal Surface Recurrence and Quantitative Association with Time to Relapse After Complete CRS/HIPEC for Colorectal Peritoneal Metastasis
Background/Objectives: Peritoneal surface metastases (PSMs) from colorectal cancer have high rates of peritoneal recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Prior studies dichotomize peritoneal recurrence into “early” and “late,” limiting insight into how clinicopathologic factors influence recurrence timing. This study aimed to identify predictors of peritoneal recurrence and quantify their continuous association with time to recurrence following CRS/HIPEC. Methods: Patients undergoing CC-0 CRS/HIPEC for colorectal PSM from 2018 to 2024 were identified from a prospectively maintained database. The primary outcome was peritoneal surface recurrence. Variables included peritoneal cancer index (PCI), tumor location, histology, HIPEC regimen, and KRAS/BRAF/SMAD4 status. Factors with p < 0.10 on univariable analysis were entered into multivariable logistic regression (recurrence: yes/no) and linear regression (time to recurrence). Results: Among 133 patients, 64 (48.1%) developed peritoneal recurrence. Median time to recurrence was 41.4 weeks (IQR 24.9–74.0), and PCI was higher among those who recurred (median 11.0 vs. 5.0, p < 0.01). Neither tumor stage, histology, intraperitoneal chemotherapy agent, nor molecular alterations were associated with increased risk of peritoneal recurrence. When controlling for PCI, right- and sigmoid-colon primaries independently predicted peritoneal recurrence compared to all other locations without influence on recurrence timing (right: OR 7.18; sigmoid: OR 6.54; p < 0.01). Among patients who recurred, each one-point increase in PCI corresponded to a 2.43-week earlier relapse (p < 0.01). Conclusions: Nearly half of patients with colorectal PSM recurred despite complete CRS/HIPEC. Tumor location predicted peritoneal recurrence, while PCI independently shortened time to relapse. Modeling PCI as a continuous predictor refines postoperative risk stratification and may inform individualized surveillance strategies.
Open AccessPredictors of Peritoneal Surface Recurrence and Quantitative Association with Time to Relapse After Complete CRS/HIPEC for Colorectal Peritoneal Metastasis
Background/Objectives: Peritoneal surface metastases (PSMs) from colorectal cancer have high rates of peritoneal recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Prior studies dichotomize peritoneal recurrence into “early” and “late,” limiting insight into how clinicopathologic factors influence recurrence timing. This study aimed to identify predictors of peritoneal recurrence and quantify their continuous association with time to recurrence following CRS/HIPEC. Methods: Patients undergoing CC-0 CRS/HIPEC for colorectal PSM from 2018 to 2024 were identified from a prospectively maintained database. The primary outcome was peritoneal surface recurrence. Variables included peritoneal cancer index (PCI), tumor location, histology, HIPEC regimen, and KRAS/BRAF/SMAD4 status. Factors with p < 0.10 on univariable analysis were entered into multivariable logistic regression (recurrence: yes/no) and linear regression (time to recurrence). Results: Among 133 patients, 64 (48.1%) developed peritoneal recurrence. Median time to recurrence was 41.4 weeks (IQR 24.9–74.0), and PCI was higher among those who recurred (median 11.0 vs. 5.0, p < 0.01). Neither tumor stage, histology, intraperitoneal chemotherapy agent, nor molecular alterations were associated with increased risk of peritoneal recurrence. When controlling for PCI, right- and sigmoid-colon primaries independently predicted peritoneal recurrence compared to all other locations without influence on recurrence timing (right: OR 7.18; sigmoid: OR 6.54; p < 0.01). Among patients who recurred, each one-point increase in PCI corresponded to a 2.43-week earlier relapse (p < 0.01). Conclusions: Nearly half of patients with colorectal PSM recurred despite complete CRS/HIPEC. Tumor location predicted peritoneal recurrence, while PCI independently shortened time to relapse. Modeling PCI as a continuous predictor refines postoperative risk stratification and may inform individualized surveillance strategies.
- 6 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2441-2442
ASO Visual Abstract: The “Textbook Outcome” Isn’t Textbook: Significant Variation in “Textbook Outcome” Definitions After a Systematic Review of the Surgical Oncology Literature
- 6 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2441-2442
ASO Visual Abstract: The “Textbook Outcome” Isn’t Textbook: Significant Variation in “Textbook Outcome” Definitions After a Systematic Review of the Surgical Oncology Literature
- 4 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2433-2434
ASO Author Reflections: Writing the Textbook on “Textbook Outcomes” in Surgical Oncology
This article reflects on the evolution, current state, and future direction of “textbook outcome” as a quality metric in surgical oncology. Originating from Ernest Codman’s early advocacy for tracking surgical outcomes, textbook outcome emerged in 2010 as a composite, all-or-nothing measure designed to capture the complete perioperative experience rather than isolated metrics. The concept gained rapid adoption in surgical oncology literature due to its patient-centered approach to outcomes.
- 4 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2433-2434
ASO Author Reflections: Writing the Textbook on “Textbook Outcomes” in Surgical Oncology
This article reflects on the evolution, current state, and future direction of “textbook outcome” as a quality metric in surgical oncology. Originating from Ernest Codman’s early advocacy for tracking surgical outcomes, textbook outcome emerged in 2010 as a composite, all-or-nothing measure designed to capture the complete perioperative experience rather than isolated metrics. The concept gained rapid adoption in surgical oncology literature due to its patient-centered approach to outcomes.
- 1 December 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2388-2401
The “Textbook Outcome” Isn’t Textbook: Significant Variation in “Textbook Outcome” Definitions following a Systematic Review of the Surgical Oncology Literature
“Textbook outcome” is an increasingly utilized composite metric used to assess postoperative outcomes in surgical oncology. Variability in R
- 1 December 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2388-2401
The “Textbook Outcome” Isn’t Textbook: Significant Variation in “Textbook Outcome” Definitions following a Systematic Review of the Surgical Oncology Literature
“Textbook outcome” is an increasingly utilized composite metric used to assess postoperative outcomes in surgical oncology. Variability in R
- 13 October 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (13) , 9473-9474
Axillary Sentinel Lymph Node Biopsy for Cutaneous Melanoma: More Work Is Not Needed
- 13 October 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (13) , 9473-9474
Axillary Sentinel Lymph Node Biopsy for Cutaneous Melanoma: More Work Is Not Needed
- 22 May 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 247, 116426
Fragmented but not necessarily flawed
- 22 May 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 247, 116426
Fragmented but not necessarily flawed
- Open Access
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS): Age-Related Outcomes and a Look into the Future
Introduction: Peritoneal carcinomatosis presents significant treatment challenges. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers a promising therapeutic approach. Patient selection remains critical, and the role of age as an exclusion criterion requires further investigation. This study evaluates whether age influences postoperative outcomes in CRS-HIPEC patients. Methods: A retrospective review of a prospective comprehensive database of 271 CRS-HIPEC procedures performed between 2018 and 2023 was conducted. Logistic regression assessed the relationship between age and postoperative outcomes. Age groups (18–44, 45–69, ≥70 years) were compared based on demographic data, primary tumor site, Peritoneal Cancer Index scores, and key outcome measures. Results: Across the different age groups, there were no significant differences in PCI scores, recurrence, disease-free survival, 30-day morbidity, or mortality. Length of stay was longer in older patients (p = 0.009). Patients aged ≥70 had higher readmission rates (p = 0.041) and were more often discharged to transitional care facilities (p = 0.001). Older patients were also more likely to experience Clavien–Dindo grade III or higher complications (p = 0.008). Logistic regression confirmed these findings. Continuous age analysis yielded similar results and revealed significant differences in race and primary organ involvement. Conclusions: Age is not a significant predictor of 30-day morbidity, mortality, or survival outcomes in patients undergoing CRS-HIPEC. However, older patients require closer attention to discharge planning and readmission risk management. This study highlights the importance of comprehensive patient assessment beyond age and underscores the need for further research to better understand factors influencing outcomes in this population.
Open AccessHyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS): Age-Related Outcomes and a Look into the Future
Introduction: Peritoneal carcinomatosis presents significant treatment challenges. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers a promising therapeutic approach. Patient selection remains critical, and the role of age as an exclusion criterion requires further investigation. This study evaluates whether age influences postoperative outcomes in CRS-HIPEC patients. Methods: A retrospective review of a prospective comprehensive database of 271 CRS-HIPEC procedures performed between 2018 and 2023 was conducted. Logistic regression assessed the relationship between age and postoperative outcomes. Age groups (18–44, 45–69, ≥70 years) were compared based on demographic data, primary tumor site, Peritoneal Cancer Index scores, and key outcome measures. Results: Across the different age groups, there were no significant differences in PCI scores, recurrence, disease-free survival, 30-day morbidity, or mortality. Length of stay was longer in older patients (p = 0.009). Patients aged ≥70 had higher readmission rates (p = 0.041) and were more often discharged to transitional care facilities (p = 0.001). Older patients were also more likely to experience Clavien–Dindo grade III or higher complications (p = 0.008). Logistic regression confirmed these findings. Continuous age analysis yielded similar results and revealed significant differences in race and primary organ involvement. Conclusions: Age is not a significant predictor of 30-day morbidity, mortality, or survival outcomes in patients undergoing CRS-HIPEC. However, older patients require closer attention to discharge planning and readmission risk management. This study highlights the importance of comprehensive patient assessment beyond age and underscores the need for further research to better understand factors influencing outcomes in this population.